Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What next for Sequenom? - a cautionary tale

This article was originally published in Clinica

Executive Summary

Allegations of falsification or misrepresentation of scientific data are not unknown in the healthcare industry, however, what has become public knowledge still can be characterised as “occasional”. Only a few days ago, Sanofi-Aventis was able to breathe a temporary sigh of relief as a federal judge dismissed a class action relating to possible increased suicidality linked to its anti-obesity drug rimonabant. Despite it having been withdrawn from the European market just months after its initial launch and not having been approved by the US FDA, the judge found that the defendants had failed to identify any specific safety data that were omitted from Sanofi-Aventis’ public disclosures.

You may also be interested in...

Biomarkers in Parkinson's disease – an open field with few obvious targets

The market for biomarkers in neurological diseases is an increasingly attractive one for many diagnostics companies. An improved understanding of the disorders and the possibility of disease-modifying drugs could lead to the discovery of more diagnostic markers and, hopefully, earlier diagnosis. In neurodegenerative illnesses, earlier intervention could stave off further loss of neurological function. This in turn would improve a patient's quality of life, and reduce the economic burden on society.

Qiagen aspires to leadership in personalised medicine

For anyone following the fastest-growing companies in the companion diagnostics sector, last month’s acquisition of DxS by Qiagen for up to $130m was no surprise. Qiagen has had its eye on personalised healthcare for quite a while now, and DxS is a very promising addition to the Venlo-based company.

Qiagen scales its way up the IVD ladder through strategic acquisitions

Diagnostics clearly is the market to invest in. The last few years have seen companies with a mainly research-oriented customer base buying in more clinically-relevant companies. Invitrogen, for example, acquired Applied Biosystems last year and now, as Life Technologies, has a prime position in the next-generation sequencing market, while Thermo Electron added a huge healthcare customer base with the Fisher acquisition of 2006 and, last month, bought biomarker expert BRAHMS. Of course, there are the players from the medtech field, such as Siemens Healthcare, which made three big diagnostics investments in DPC, Bayer’s diagnostics business and Dade-Behring. Even an established diagnostics company like Beckman Coulter continues to buy in new assets and expand its geographical reach, such as with the Olympus diagnostics unit.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts